Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIPO23 Phase I/II XON7 in Advanced or Metastatic Solid Tumors
2023-505266-29-00Phase 2Authorised
- Sponsor
- Xenothera
- Start
- Sep 2023
- Modality
- Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of X0N7 in Nonhematologic neoplasms, sponsored by Xenothera. Primary endpoints: Safety and tolerability of XON7, Pharmacokinetics of XON7 and 1 more. Planned start Sep 2023; status: authorised.
02
Drugs
X0N7
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on 2023-505266-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505266-29-00.